The Weekly Recap 10/31/25: LSI Alumni Achievements Driving Medtech and Healthtech Forward

In a successful week for the medical technology companies in the LSI Alumni community, we saw LSI Alumni announce regulatory wins, achieve clinical milestones, appoint new executives, and much more on the road to LSI USA ’26 in Dana Point (March 16–20).

Avvio Medical

Received FDA Breakthrough Device Designation for its Enhanced Lithotripsy System (ELS), a minimally invasive platform designed to treat kidney stones without general anesthesia, fluoroscopy, or costly capital equipment. The designation accelerates the company’s path to De Novo submission in 2026 and supports its mission to move kidney stone treatments out of the OR and into more accessible outpatient settings.

Earlybird Health

Promoted Dr. Rabab Nasrallah and LSI Alumni Dr. Christoph Massner to Partners at Earlybird Health in recognition of their leadership across biotech, medtech, and data-driven health investments. The promotion reflects their impact on investment strategy and portfolio management, further strengthening Earlybird Health’s commitment to rigorous, future-focused healthcare innovation.

Elixir Medical

Announced new landmark clinical results for the DynamXⓇ bioadaptor coronary implant system. Data presented at the 2025 Transcatheter Cardiovascular Therapeutics conference showed a 48% risk reduction in device-related cardiac events compared to a current-generation drug-eluting stent.

Inner Cosmos

Completed its FDA early feasibility trial for the Digital Pill, a minimally invasive implantable device designed to treat treatment-resistant depression. The system is implanted subdermally and magnetically connects to an external pod, enabling patients to self‑administer transcranial magnetic stimulation‑like therapy at home.

Innitius

Received CE Marking for CerviSenseⓇ, an operator-independent diagnostic platform that assesses cervical stiffness for obstetric decision-making. The certification enables European commercialization and supports broader adoption of the technology to improve outcomes in preterm birth management and labor induction.

magAssist

Appointed Steve Motes as Chief Executive Officer for its U.S. operations, bringing 25+ years of leadership experience in the medical device industry and deep expertise across advanced circulatory support and critical-care technologies. His leadership is expected to strengthen the company’s presence in the U.S. cardiovascular market and accelerate its broader global growth strategy.

This blog is originally published here: https://www.lifesciencemarketresearch.com/insights/the-weekly-recap-103125-lsi-alumni-achievements-driving-medtech-and-healthtech-forward

Comments

Post a Comment

Popular posts from this blog

Cover Story: A Page from Ray Cohen’s Playbook: Scaling, Exiting, and Winning in Medtech

With four decades of company-building, IPOs, boardroom leadership, and monumental exits behind him, Raymond W. Cohen has become one of medtech’s most successful operators. But behind the financial wins — including the recent back-to-back $3.7 billion Axonics and $600 million SoniVie acquisitions by Boston Scientific — is a deeper story of Cohen’s contrarian, full-transparency, people-centered, no-BS approach to leadership and strategy. “People crave inspired, authentic, and transparent leadership that thinks big and acts boldly. They want to be enrolled in a vision of what is possible, and be recognized and compensated for creating measurable results, not be fed a bunch of platitudes.” A quote that is classic  Ray Cohen  — blunt, unapologetic, no-nonsense, and grounded in hard-won experience. With more than four decades in medtech, Cohen has done what many aspire to — build, lead, scale, and sell high-stakes, successful ventures with precision and zero fluff. Known for his no-...
Read more

The Weekly Recap 6/13/25: LSI Alumni Achievements Driving Medtech and Healthtech Forward

In a successful week for the medical technology companies in the LSI Alumni community, we saw LSI Alumni secure over $63M in new funds, receive FDA 510(k) clearances, announce an acquisition, and much more as we wind down   LSI Asia  ’25 in Singapore and gear up for  LSI Europe  ’25 in London (September 7–11). Accelus Received FDA 510(k) clearance for the FlareHawk Interbody Fusion System to be safely subjected to MRI scanning in certain conditions. The clearance supports Accelus’s commitment to safe, high-performance spinal solutions and expands imaging options for patients with FlareHawk implants. Aortyx Raised $16M to advance its bioresorbable aortic patch toward first-in-human trials. The funding supports continued development of Aortyx’s minimally invasive, tissue-regenerating solution for aortic dissection and positions the company for clinical entry within two years. Atraverse Medical Closed $29.4M in follow-on financing to scale U.S. commercialization of HOTW...
Read more

Medtech in 2025: Key Insights from Q1 Earnings

  As we venture into Q2 of 2025, the medtech industry continues to navigate challenges while remaining on a positive growth trajectory. The early earnings reports from major medtech companies provide valuable insights into how the sector is performing and where it is heading. Despite the pressures of ongoing macroeconomic uncertainty, the first quarter of 2025 shows a sector that’s resilient, with many companies reporting strong growth across their key divisions. For more information visit here:  https://www.slideshare.net/slideshow/medtech-in-2025-key-insights-from-q1-earnings/279045324
Read more